P38 One Size Does Not Fit All: Calculating the Cost-Effectiveness of Multiple Indications of Pembrolizumab in the Netherlands
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.050
https://www.valueinhealthjournal.com/article/S1098-3015(22)02252-5/fulltext
Section Title :
Section Order :
12244
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02252-5&doi=10.1016/j.jval.2022.09.050